Published in N Engl J Med on June 29, 1989
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med (2003) 4.68
Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood (2010) 4.46
Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med (2007) 4.14
Evolutionary struggles between NK cells and viruses. Nat Rev Immunol (2008) 3.79
Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A (2009) 3.74
Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood (2011) 3.66
Expansion of a unique CD57⁺NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A (2011) 3.53
Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J Exp Med (2010) 2.89
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood (2013) 2.82
Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med (1990) 2.79
Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev (2009) 2.75
NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J Exp Med (2003) 2.75
The Yin and Yang of HLA and KIR in human disease. Semin Immunol (2008) 2.72
Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A (2004) 2.66
'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection. Nat Immunol (2010) 2.57
Beta 2-microglobulin-, CD8+ T-cell-deficient mice survive inoculation with high doses of vaccinia virus and exhibit altered IgG responses. Proc Natl Acad Sci U S A (1992) 2.37
Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J Virol (1997) 2.35
Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways. J Exp Med (1998) 2.34
Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood (2007) 2.32
Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc Natl Acad Sci U S A (2002) 2.32
Epistasis between mouse Klra and major histocompatibility complex class I loci is associated with a new mechanism of natural killer cell-mediated innate resistance to cytomegalovirus infection. Nat Genet (2005) 2.31
Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med (2003) 2.20
CD4(+) T cell-mediated control of a gamma-herpesvirus in B cell-deficient mice is mediated by IFN-gamma. Proc Natl Acad Sci U S A (1999) 2.14
Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol (2012) 1.98
Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Acad Sci U S A (2011) 1.98
Recognition of herpesviruses by the innate immune system. Nat Rev Immunol (2011) 1.96
Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset. Blood (2013) 1.93
Modulation of natural killer cells by human cytomegalovirus. J Clin Virol (2008) 1.90
Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat Immunol (2005) 1.86
Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J Clin Invest (2002) 1.83
HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. Blood (2007) 1.83
Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest (2011) 1.82
IL-18-induced CD83+CCR7+ NK helper cells. J Exp Med (2005) 1.76
Natural killer cell deficiency. J Allergy Clin Immunol (2013) 1.74
A role for NKG2D in NK cell-mediated resistance to poxvirus disease. PLoS Pathog (2008) 1.72
Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity (2015) 1.71
HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response. PLoS Pathog (2009) 1.71
Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses. J Exp Med (2000) 1.69
Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity (2015) 1.68
NK cells and immune "memory". J Immunol (2011) 1.66
The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions. J Exp Med (2004) 1.63
Induction of natural killer cell responses by ectromelia virus controls infection. J Virol (2007) 1.62
Hidden talents of natural killers: NK cells in innate and adaptive immunity. EMBO Rep (2009) 1.60
Herpes simplex virus infection is sensed by both Toll-like receptors and retinoic acid-inducible gene- like receptors, which synergize to induce type I interferon production. J Gen Virol (2009) 1.56
Human-specific evolution of killer cell immunoglobulin-like receptor recognition of major histocompatibility complex class I molecules. Philos Trans R Soc Lond B Biol Sci (2012) 1.55
Natural killer cells utilize both perforin and gamma interferon to regulate murine cytomegalovirus infection in the spleen and liver. J Virol (2005) 1.55
Delineation of multiple subpopulations of natural killer cells in rhesus macaques. Immunology (2005) 1.50
NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection. J Intern Med (2009) 1.50
Ly49P recognition of cytomegalovirus-infected cells expressing H2-Dk and CMV-encoded m04 correlates with the NK cell antiviral response. J Exp Med (2009) 1.45
Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med (2004) 1.44
Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog. J Exp Med (1998) 1.43
Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am (2011) 1.42
Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol (2008) 1.42
Major histocompatibility complex class I antigens and the control of viral infections by natural killer cells. J Virol (1995) 1.40
Biallelic mutations in IRF8 impair human NK cell maturation and function. J Clin Invest (2016) 1.39
Natural killer cell tolerance in mice with mosaic expression of major histocompatibility complex class I transgene. J Exp Med (1997) 1.38
Immune memory redefined: characterizing the longevity of natural killer cells. Immunol Rev (2010) 1.36
UL40-mediated NK evasion during productive infection with human cytomegalovirus. Proc Natl Acad Sci U S A (2002) 1.36
Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J Clin Invest (2012) 1.35
The switch from latent to productive infection in epstein-barr virus-infected B cells is associated with sensitization to NK cell killing. J Virol (2006) 1.35
Cutting edge: antibody-dependent memory-like NK cells distinguished by FcRγ deficiency. J Immunol (2013) 1.35
Ly49h-deficient C57BL/6 mice: a new mouse cytomegalovirus-susceptible model remains resistant to unrelated pathogens controlled by the NK gene complex. J Immunol (2008) 1.33
Cell type-specific regulation of IL-10 expression in inflammation and disease. Immunol Res (2010) 1.32
Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome). J Exp Med (1998) 1.31
Herpes simplex virus infection of human fibroblasts and keratinocytes inhibits recognition by cloned CD8+ cytotoxic T lymphocytes. J Clin Invest (1993) 1.31
The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1- NK cells. J Immunol (2007) 1.29
Inherited and acquired immunodeficiencies underlying tuberculosis in childhood. Immunol Rev (2015) 1.29
HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes. Proc Natl Acad Sci U S A (2003) 1.27
Epstein-Barr virus BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells. J Virol (1999) 1.27
Stat4-dependent, T-bet-independent regulation of IL-10 in NK cells. Genes Immun (2008) 1.26
KIR/HLA interactions and pathogen immunity. J Biomed Biotechnol (2011) 1.26
Toll-like receptors: key players in antiviral immunity. Curr Opin Virol (2011) 1.24
Interplay between alpha/beta and gamma interferons with B, T, and natural killer cells in the defense against herpes simplex virus type 1. J Virol (2004) 1.24
TLR3 deficiency renders astrocytes permissive to herpes simplex virus infection and facilitates establishment of CNS infection in mice. J Clin Invest (2012) 1.24
Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection. PLoS Pathog (2010) 1.22
NK cells, displaying early activation, cytotoxicity and adhesion molecules, are associated with mild dengue disease. Clin Exp Immunol (2006) 1.22
A novel primary immunodeficiency with specific natural-killer cell deficiency maps to the centromeric region of chromosome 8. Am J Hum Genet (2006) 1.22
Recognition of virus-infected cells by natural killer cell clones is controlled by polymorphic target cell elements. J Exp Med (1993) 1.21
Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro. J Virol (1999) 1.21
Natural Killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin Exp Immunol (1996) 1.20
Role of human natural killer cells in health and disease. Clin Diagn Lab Immunol (1994) 1.19
IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion. J Clin Invest (2014) 1.17
Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything. J Intern Med (2010) 1.17
Ly49H signaling through DAP10 is essential for optimal natural killer cell responses to mouse cytomegalovirus infection. J Exp Med (2009) 1.16
Natural killer cell receptors specific for major histocompatibility complex class I molecules. Proc Natl Acad Sci U S A (1995) 1.16
In vivo natural killer cell depletion during primary simian immunodeficiency virus infection in rhesus monkeys. J Virol (2008) 1.15
Natural killer cells and autoimmunity. Arthritis Res Ther (2003) 1.14
Primate-specific regulation of natural killer cells. J Med Primatol (2010) 1.14
IFN-gamma, produced by NK cells that infiltrate liver allografts early after transplantation, links the innate and adaptive immune responses. Am J Transplant (2005) 1.14
Innate and adaptive immune responses to herpes simplex virus. Viruses (2009) 1.14
Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J Clin Invest (2002) 1.14
ATF3 regulates MCMV infection in mice by modulating IFN-gamma expression in natural killer cells. Proc Natl Acad Sci U S A (2008) 1.13
Ly49h is necessary for genetic resistance to murine cytomegalovirus. Immunogenetics (2008) 1.12
Memory-like responses of natural killer cells. Immunol Rev (2010) 1.11
NK cell response to vaccinia virus is regulated by myeloid-derived suppressor cells. J Immunol (2012) 1.11
The immune response to human CMV. Future Virol (2012) 1.10
Natural killer cells in human autoimmune disorders. Arthritis Res Ther (2013) 1.10
T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase. J Clin Invest (1993) 1.09
H5-type influenza virus hemagglutinin is functionally recognized by the natural killer-activating receptor NKp44. J Virol (2007) 1.08
Changes in thymic function with age and during the treatment of HIV infection. Nature (1998) 10.27
Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med (1995) 8.15
Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med (1996) 4.44
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med (2000) 4.12
Iron and the sex difference in heart disease risk. Lancet (1981) 3.45
High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J Virol (1996) 2.61
Detection of major histocompatibility complex class I-restricted, HIV-specific cytotoxic T lymphocytes in the blood of infected hemophiliacs. Blood (1989) 2.37
Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med (1992) 2.33
Immune response after splenectomy. Lancet (1978) 2.31
Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res (1981) 2.25
Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis (1998) 2.08
Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. J Virol (2000) 2.04
Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol (2000) 2.04
High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis (1995) 1.97
Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J Virol (1989) 1.87
Measles infection of human mononuclear cells. I. Acute infection of peripheral blood lymphocytes and monocytes. J Exp Med (1975) 1.86
Influenza virus infection in nude mice. J Infect Dis (1976) 1.85
Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS. J Virol (2001) 1.80
Characterization of the T cell-mediated cellular cytotoxicity during acute infectious mononucleosis. J Immunol (1989) 1.77
Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by Epstein-Barr virus complementary RNA/DNA and viral DNA/DNA hybridization. Cancer Res (1981) 1.72
Infrequent detection of HIV-1-specific, but not cytomegalovirus-specific, CD8(+) T cell responses in young HIV-1-infected infants. J Immunol (2001) 1.72
HIV-1-specific cytotoxic T lymphocyte responses in the first year of life. J Immunol (1995) 1.69
Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. N Engl J Med (1999) 1.69
Aetiology of AIDS--antibodies to human T-cell leukaemia virus (type III) in haemophiliacs. Nature (1984) 1.63
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother (1993) 1.62
Sequence variations in human immunodeficiency virus type 1 Nef are associated with different stages of disease. J Virol (1999) 1.61
High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice. J Infect Dis (1995) 1.58
Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. N Engl J Med (1997) 1.56
Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.55
Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol (1999) 1.54
Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1. AIDS (1991) 1.53
Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses (1994) 1.51
Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med (1997) 1.50
"Chronic Epstein-Barr virus infection" syndrome and polymyalgia rheumatica. J Rheumatol (1988) 1.50
Serological characterization of HTLV-III infection in AIDS and related disorders. J Infect Dis (1986) 1.47
Inhibition of lymphocyte stimulation by measles virus. J Immunol (1975) 1.47
On the antioxidant properties of erythropoietin and its association with the oxidative-nitrosative stress response to hypoxia in humans. Acta Physiol (Oxf) (2014) 1.43
Antioxidants and coronary heart disease. Lancet (1991) 1.43
Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol (1987) 1.42
Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo. J Infect Dis (1997) 1.41
Reactive histiocytic disorders. Am J Clin Pathol (1993) 1.41
Vertical transmission of Mycobacterium tuberculosis in KwaZulu Natal: impact of HIV-1 co-infection. Int J Tuberc Lung Dis (2004) 1.39
Racial/ethnic differences in HIV-1 seroprevalence and risky behaviors among intravenous drug users in a multisite study. Am J Epidemiol (1990) 1.38
Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection. J Immunol (2001) 1.37
Cell-mediated immunity to Epstein-Barr-virus-transformed lymphoblastoid cells in acute infectious mononucleosis. N Engl J Med (1975) 1.36
IL-2 independent growth and cytotoxicity of herpesvirus saimiri-infected human CD8 cells and involvement of two open reading frame sequences of the virus. Virology (1993) 1.35
Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J (2001) 1.34
Soluble CD8 during T cell activation. J Immunol (1989) 1.34
Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children. J Pediatr (1991) 1.32
Frequency of 'chronic active Epstein-Barr virus infection' in a general medical practice. JAMA (1987) 1.31
Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J Infect Dis (1991) 1.26
Deficient natural killer cell activity in x-linked lymphoproliferative syndrome. Science (1980) 1.25
Phenotypic manifestations of Gaucher disease: clinical features in 48 biochemically verified type 1 patients and comment on type 2 patients. Prog Clin Biol Res (1982) 1.24
Detection of cell-free Epstein-Barr virus DNA in serum during acute infectious mononucleosis. J Infect Dis (1994) 1.23
Immunological bases for superior survival of females. Am J Dis Child (1979) 1.22
Adenosine deaminase activity in lymphocytes. Br J Haematol (1977) 1.21
Retinopathy of prematurity and iron: a modification of the oxygen hypothesis. Pediatrics (1986) 1.20
Early HIV-1 envelope-specific cytotoxic T lymphocyte responses in vertically infected infants. J Exp Med (1997) 1.19
The in vitro growth, heterotransplantation, and differentiation of a human rhabdomyosarcoma cell line. Am J Pathol (1986) 1.18
Atypical depression. Arch Gen Psychiatry (1982) 1.18
Pathogenesis of B cell lymphoma in a patient with AIDS. Blood (1986) 1.18
Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants. Pediatr Infect Dis J (2001) 1.18
Early viremia and immune responses in vertical human immunodeficiency virus type 1 infection. J Infect Dis (1993) 1.16
Caffeine poisioning in an infant. J Pediatr (1977) 1.15
Effect of HIV on thymic function before and after antiretroviral therapy in children. J Infect Dis (2000) 1.14
Myocarditis presenting as acute myocardial infarction. Am Heart J (1988) 1.14
Resistance to apoptosis in HIV-infected CD4+ T lymphocytes is mediated by macrophages: role for Nef and immune activation in viral persistence. J Immunol (2000) 1.14
X-linked lymphoproliferative syndrome registry report. J Pediatr (1980) 1.13
Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis (1996) 1.12
Hemophiliac immunodeficiency: influence of exposure to factor VIII concentrate, LAV/HTLV-III, and herpesviruses. J Pediatr (1986) 1.11
Comparative trial of influenza vaccines. II. Adverse reactions in children and adults. Am J Epidemiol (1976) 1.11
Immune responses during measles infection in immunosuppressed Rhesus monkeys. J Immunol (1977) 1.10
Epstein-Barr virus-associated hemophagocytic syndrome: virological and immunopathological studies. Blood (1985) 1.06
Human peripheral blood xenografts in the SCID mouse: characterization of immunologic reconstitution. J Infect Dis (1993) 1.04
Long-term nonprogressive infection with human immunodeficiency virus type 1 in a hemophilia cohort. J Infect Dis (1999) 1.03
Dyskinesias associated with tricyclic antidepressants. Br J Psychiatry (1976) 1.03
The changing face of pediatric HIV-1 infection. N Engl J Med (2001) 1.02
Inositol-less death in Neurospora and cellular ageing. Nat New Biol (1973) 1.01
Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by clinical, virological, and immunopathological studies. Cancer Res (1981) 1.01
Isolation of human immunodeficiency virus from hemophiliacs: correlation with clinical symptoms and immunologic abnormalities. J Pediatr (1987) 1.01
Quantitation of human immunodeficiency virus in vertically infected infants and children. J Pediatr (1991) 0.99
Delayed cutaneous hypersensitivity reactions in hemophiliac subjects treated with factor concentrate. Am J Med (1986) 0.99
Detection of HIV-1-infected cells from patients using nonisotopic in situ hybridization. Blood (1989) 0.98
X-linked lymphoproliferative syndrome. Natural history of the immunodeficiency. J Clin Invest (1983) 0.98
Delayed generation of antibodies mediating human immunodeficiency virus type 1-specific antibody-dependent cellular cytotoxicity in vertically infected infants. WITS Study Group. Women and Infants Transmission Study. J Infect Dis (1997) 0.98
Epstein-Barr-virus induced lymphoproliferation. Implications for antiviral chemotherapy. N Engl J Med (1984) 0.97
Subcellular localization of low-abundance human immunodeficiency virus nucleic acid sequences visualized by fluorescence in situ hybridization. Proc Natl Acad Sci U S A (1990) 0.97
Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice. J Immunol (2000) 0.96
Acute epiglottitis. Review of 55 cases and suggested protocol. Arch Otolaryngol (1974) 0.96
Mapping the X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A (1987) 0.95
Virologic studies in a case of transfusion-associated AIDS. N Engl J Med (1984) 0.95
Community-wide HIV counselling and testing in central Massachusetts: who is retested and does their behavior change? J Community Health (1996) 0.94